Cancer Drug Resistance

SJR Rank #1,791H-index: 36SJR: 1.775Best quartile: Q1
Journal website: aims, scope and author guidelines
Publisher

OAE Publishing Inc.

Country

United States

Type

journal

SJR by Edition

2022202500.450.91.351.8

Subject Categories

  • Cancer ResearchQ1
  • Pharmacology (medical)Q1

Areas: Biochemistry, Genetics and Molecular Biology · Medicine

Most published research topics

Cancer Immunotherapy and BiomarkersCancer Cells and MetastasisCancer Genomics and DiagnosticsMicroRNA in disease regulationEpigenetics and DNA MethylationCancer, Hypoxia, and MetabolismCancer therapeutics and mechanismsCancer-related molecular mechanisms researchHistone Deacetylase Inhibitors ResearchFerroptosis and cancer prognosis

Source: OpenAlex

Publication Statistics

2025 Docs3-Year DocsCitable Docs04590135180

Documents per Year

20222025020406080

Detailed Information

ISSN

2578-532X

SJR Best Quartile

Q1

Region

Northern America

Citations per Document (2 years)

6.92

References per Document

117.15

Coverage

2018-2025

Scope

Cancer Drug Resistance is a quarterly published journal committed to the rapid publication of high quality, peer-reviewed, original researches. The journal publishes research articles, reviews, case reports, commentaries and letters on pharmacological aspects of drug resistance and its reversal, including drug design, drug delivery, drug distribution and cellular drug resistance. Molecular mechanisms of drug resistance also cover the cellular pharmacology of drug resistance such as influx and efflux pumps (including the ABC pumps), receptors and their ligands, cellular signaling pathways, drug activation and degradation (including Phase I and II metabolism), drug sequestration, target modification and DNA repair. Drug classes to be covered include DNA targeted drugs and antihormones as well as antibodies and protein kinase inhibitors. Both clinical and experimental aspects of drug resistance in cancer are included.

Metrics from SCImago Journal Rank 2025. View on SCImago